Actuate Therapeutics Inc

ACTU | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.91

-$0.07 (-7.26%)

At close: Sep 21, 2026, 4:00 PM ET

$1

+$0.09 (+9.88%)

Pre-market: Sep 22, 2026, 9:18 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $21.71M

Enterprise Value $17.69M

Beta 0.78

Average Volume 300.12K

Shares Outstanding (Diluted) 23.87M

Shares Change YoY 21.51%

Institutional Ownership 58.88%

Exchange NASDAQ

ISIN US0050831009

Price Performance

Price Change 1M -28.9%

Price Change 3M -52.9%

Price Change 6M -60.8%

Price Change YTD -84.9%

Price Change 1Y -87.2%

Price Change 3Y -89.5%

Price Change 5Y -89.5%

1M CAGR (ann.) -18.3%

1Y CAGR (ann.) -86.8%

5Y CAGR (ann.) N/A

All-Time CAGR -65.6%

Valuation

PE Ratio -1.02

Forward PE N/A

PEG Ratio -0.01

Forward PEG 0.12

PS Ratio N/A

Forward PS 3.50

PB Ratio 21.95

P/FCF Ratio -1.09

P/Adj. FCF Ratio -0.84

P/OCF Ratio -1.10

EV/Sales N/A

EV/EBIT -0.86

EV/EBITDA -0.86

EV/FCF -0.89

Earnings Yield -97.8%

FCF Yield -91.4%

Adj. FCF Yield -119.2%

Financial Health

Net Cash $4.02M

Total Debt $404.99K

Cash & Short-Term Investments $4.43M

Total Assets $5.2M

Current Ratio 1.25

Quick Ratio 1.25

Debt / Equity Ratio 0.41

Debt / EBITDA -0.02

Debt / FCF -0.02

OCF / Debt -48.98

Interest Coverage -1,025.81

Altman Z-Score -54.14

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -30.4%

Returns

Return on Assets -393.4%

Return on Equity -346.2%

Return on Invested Capital -1490.0%

Return on Capital Employed -1490.0%

Return on Tangible Assets -393.4%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 30.3%

EPS CAGR 5Y N/A

EPS CAGR 10Y N/A

FCF CAGR 3Y -1.9%

FCF CAGR 5Y N/A

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 1

EPS Growth Next 3Y 26.2%

Revenue Growth Next 3Y N/A

Earnings Date Nov 11, 2026

EPS Estimate (next Q) -$0.18

EPS Growth Est (next Q) -28.0%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $21

Price Target Upside 2207.7%

Cash Flow

Operating Cash Flow $-19.84M

Free Cash Flow $-19.84M

Adj. Free Cash Flow $-25.88M

FCF Per Share -$0.83

OCF Per Share -$0.83

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $0

Operating Income $-20.77M

EBITDA $-20.48M

Net Income $-20.45M

EPS (Diluted) -$0.89

Revenue / Employee N/A

Profit / Employee $-1.7M

Employees 12